TuesdayAug 31, 2021 10:49 am

Experts Recommend That Colorectal Cancer Screening Start at Age 45

The U.S Preventive Services Task Force recently issued a guideline recommending that people at average risk for colorectal cancer start undergoing screening exams when they’re 45, as opposed to the conventional 50 years. This recommendation was prompted by the recent increase in colorectal cancer cases in individuals who are below 50. These changes, which were published on JAMA Network, align with recommendations from the American Cancer Society. Colorectal cancer is sometimes referred to as rectal cancer, colon cancer or bowel cancer. It usually begins in the rectum or colon, which make up part of the large intestine. Most cases of…

Continue Reading

MondayAug 30, 2021 11:32 am

New Study Explores Complex Trauma and Association with Future Mental Health Illnesses

The results of new study investigating the different types of trauma and whether they confer a risk of mental illness in the future has been released. The pioneering research, which was published in the “British Journal of Psychiatry,” was conducted by researchers from King’s College London. The researchers looked into the theory suggesting that traumas involving interpersonal violence that occurs repetitively at an early age could depict a damaging type of trauma known as complex trauma. The participants who took part in the study were recruited from the E-Risk study. This study tracks the development of more than 2,200 children…

Continue Reading

MondayAug 30, 2021 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Files Patent Applications to Support Research Phase Programs, Strengthen IP Portfolio

Company’s nonprovisional patent application includes claims to compositions, methods to support certain elements of preclinical and research programs Two international patent applications will grant Cybin the right to file future national applications into treaty member jurisdictions Cybin portfolio consists of 14 patent filings, 50-plus proprietary molecules, 50-plus preclinical studies and 4 active drug programs Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, is moving forward to progress and strengthen its IP portfolio by filing three patents this month. After receiving an international search report of its May 2021 Patent Cooperation Treaty (“PCT”) application, Cybin…

Continue Reading

FridayAug 27, 2021 1:33 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), At the Forefront of the Psychedelic Renaissance

Psychedelics date back to ancient times, with records showing their use among the Aztecs as well as cultures in North Africa and Europe for medicinal and cultural purposes The prohibition era marked significant strides in psychedelics research, including the ultimate prohibition of the possession, sale and manufacture of psychedelics The 21st century has seen a surge in psychedelics research, a critical factor that has initiated a renaissance in this industry Tryp Therapeutics remains at the forefront of this renaissance with its commitment to identifying and developing clinical-stage compounds for diseases with high unmet medical needs, like Fibromyalgia and Eating Disorder…

Continue Reading

FridayAug 27, 2021 12:54 pm

Study Finds That Sleep Apnea Increases Risk of Sudden Death

Research conducted by Penn State College of Medicine has discovered that individuals who are diagnosed with obstructive sleep apnea have a higher risk of sudden death in comparison with individuals who don’t have sleep apnea. Estimates show that more than one billion people globally suffer from this chronic sleep disorder. The disorder causes a blockage of airflow when an individual is sleeping. This disturbance can also manifest as non-refreshing sleep, heavy snoring, fatigue and excessive daytime sleepiness. The study was published in “BMJ Open Respiratory Research.” The researchers conducted a systematic literature review and identified more than 20 studies focusing…

Continue Reading

FridayAug 27, 2021 10:44 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Presents CBN-Based Treatment for Glaucoma at H.C. Wainwright Ophthalmology Virtual Conference

The presentation highlighted the company’s INM-088 cannabinol topical eye drop to treat glaucoma InMed’s IntegraSyn is being used to help the company develop synthetic bioidentical rare cannabinoids in the lab, as most are only found in trace amounts in cannabis plants In addition to INM-088 for glaucoma, the company is currently working on CBN-based INM-755 to treat a rare genetic skin disorder called epidermolysis bullosa and is awaiting the answer to Phase II trial applications in various countries Dedicated to delivering new therapeutic alternatives as a treatment for conditions with a high unmet medical need, InMed Pharmaceuticals (NASDAQ: INM) is…

Continue Reading

ThursdayAug 26, 2021 12:06 pm

Molecular Approaches May Help Accurately Diagnose Lesions in Drug-Resistant Focal Epilepsy

A recently published review has discovered that considering genetic data for individuals who are suffering from drug-resistant focal epilepsy has led to the definition of novel illness entities and enhanced clinical decision making. Drug-resistant focal epilepsy, as defined by the International League Against Epilepsy, usually occurs when an individual has failed to stay free of seizures with sufficient trials of 2 ASMs (anti-seizure medication). The disease is often caused by brain lesions such as glioneural tumors. These drugs must have been specifically chosen for the individual’s type of seizures and tried in combination with other seizure medications or on their…

Continue Reading

ThursdayAug 26, 2021 10:44 am

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Names CEO of AnPac Bio U.S. to Drive Adoption of Early Cancer Detection Technology

Early cancer detection technology innovator AnPac Bio-Medical Science Co. Ltd. has been awarded 142 patents with 95 patents pending as part of its bid to revolutionize cancer screening protocols AnPac Bio’s proprietary technology screens for a variety of biophysical properties and analyzes the results to establish risk factors for tumor development before tumor cells begin circulating in the bloodstream AnPac Bio’s technology can be combined with the more extant tumor cell-detection technology to boost the screening’s effectiveness The international company, with operations in the US and China recently named an accomplished bio-medical executive, Dr. Sunil Pandit, as the CEO of…

Continue Reading

WednesdayAug 25, 2021 12:31 pm

Study Looks Into Mutations That Cause Resistance to Cancer Therapies

A study conducted by researchers from UT Southwestern has discovered that mutating genes to create proteins that drive cancer using a virus may allow scientists to better understand the resistance that develops to the cancer treatments used to target them. The researchers’ findings were published in “Cancer Research,” with the scientists noting that their discovery could assist in better understanding the interaction between treatments and their target proteins, as well as in the development of treatments that bypass resistance. Dr. Ralf Kittler from the Eugene McDermott Center for Human Growth and Development, who is the research leader, stated that the…

Continue Reading

WednesdayAug 25, 2021 11:05 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Pursues Commercial Production of Rare Cannabinoids at Pharmaceutical Levels

Canadian clinical-stage drug development company InMed Pharmaceuticals is working to achieve pharmaceutical approval of rare cannabinoids InMed Pharmaceutical has developed a trademarked platform called IntegraSyn that extracts five times the normally expected yields of cannabinoids from its plant sources IntegraSyn’s ability to increase yields may ultimately help InMed to achieve a profitable means of producing cannabinol (“CBN”) and other lesser-known cannabinoids at commercial scales To date, GW Pharma’s Epidiolex is the only cannabis-derived product to achieve FDA approval as a pharmaceutical, and the company’s multi-million-dollar revenues demonstrate the potential returns a pharmaceutical-level drug can achieve British Columbia, Canada-based InMed Pharmaceuticals…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050